Related Experiment Video
Updated: Feb 25, 2026
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
5-Azacytidine specifically inhibits the NIH-3T3 PCD process induced by TNF-alpha and cycloheximide via affecting
Abstract:
DNA methylation plays a crucial role in lots of biological processes and cancer. 5-azacytidine (5-AC), a DNA methylation inhibitor, has been used as a potential chemotherapeutic agent for cancer. In this study, we used 5-AC treatment to investigate whether DNA methylation was involved in regulation of programmed cell death (PCD) in mouse embryo fibroblast NIH-3T3 cells which could undergo PCD after treatment with TNF-α and cycloheximide (CHX). The results showed that the genomic DNA of NIH-3T3 cells was hypermethylated during PCD induced by TNF-α and CHX, and 5-AC might prevent this PCD process. However, treatment with the other three DNA methylation inhibitors, 5-aza-deoxycytidine, 6-thioguanine and RG108, did not interfere with the NIH-3T3 cell PCD process. Additionally, knockdown of DNMT1 did not affect the apoptosis process. The present results and observations indicated that 5-AC specifically inhibited the NIH-3T3 apoptosis process via a genomic DNA methylation-independent pathway. During the TNF-α and CHX-inducing apoptosis process, the PCD related BCL-2 family proteins were significantly down-regulated. Furthermore, after the small interference RNA-mediated knockdown of BCL-XL, one of the BCL-2 family proteins, 5-AC did not inhibit the apoptosis process, suggesting that 5-AC inhibited the PCD process induced by TNF-α and CHX by affecting the anti-apoptotic protein BCL-XL.
Insights
5-azacytidine (5-AC) inhibits programmed cell death (PCD) in NIH-3T3 cells, but not through DNA methylation. Instead, 5-AC affects the anti-apoptotic protein BCL-XL, revealing a novel mechanism for cancer therapy research.
Area of Science:
- Molecular Biology
- Cell Biology
- Cancer Research
Background:
- DNA methylation is vital in biological processes and cancer.
- 5-azacytidine (5-AC) is a DNA methylation inhibitor explored for cancer chemotherapy.
- Programmed cell death (PCD) regulation is crucial in cancer development.
Purpose of the Study:
- To investigate 5-AC's role in PCD regulation in NIH-3T3 cells.
- To determine if DNA methylation mediates 5-AC's effect on PCD.
- To elucidate the specific molecular pathway targeted by 5-AC during PCD.
Main Methods:
- Treatment of NIH-3T3 cells with TNF-α and cycloheximide (CHX) to induce PCD.
- Application of 5-AC and other DNA methylation inhibitors.
- Assessment of genomic DNA methylation levels.
- Knockdown of DNMT1 and BCL-XL using small interference RNA.
- Analysis of BCL-2 family protein expression.
Main Results:
- Genomic DNA hypermethylation occurred during TNF-α/CHX-induced PCD.
- 5-AC appeared to prevent PCD, but this effect was independent of DNA methylation.
- Other DNA methylation inhibitors and DNMT1 knockdown did not affect PCD.
- BCL-2 family proteins, including BCL-XL, were downregulated during PCD.
- 5-AC's inhibition of PCD was abolished by BCL-XL knockdown.
Conclusions:
- 5-AC inhibits TNF-α/CHX-induced PCD in NIH-3T3 cells via a DNA methylation-independent pathway.
- The anti-apoptotic protein BCL-XL is a key target of 5-AC in this PCD process.
- These findings suggest BCL-XL modulation as a potential therapeutic strategy in cancer treatment.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
02:34Inhibition of Cdk Activity
01:31The Intrinsic Apoptotic Pathway